Drug

Travoprost

Established medicine

ClassProstanoid FP receptor agonistResearchOngoing clinical research

Also known as OTX-TP, TRAVOPROST COMPONENT OF DUOTRAV, Travatan, iDose+4 more

OTX-TP, TRAVOPROST COMPONENT OF DUOTRAV, Travatan, iDose, travoprost ophthalmic, (1R-(1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.))-7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOIC ACID, 1-METHYLETHYL ESTER, ISOPROPYL (Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3R)-3-HYDROXY-4-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATE, Travoprostum.

RxNorm283809 ChEMBLCHEMBL1200799 ATCS01EE04UNIIWJ68R08KX9

Prostaglandin F2-alpha receptor

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Stop Retinal Ganglion Cell Dysfunction Study

Clinical trial2024-10-04Terminated · ClinicalTrials.gov

Prospective, Non-Randomized, Open-Label, Multi-Center, Single Arm Study of Exchange of Travoprost Intraocular Implant

Clinical trial2023-09-26Results posted · ClinicalTrials.gov

A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension

Clinical trial2021-10-11Results posted · ClinicalTrials.gov

The Effects of Topical Beta Blocker and Prostaglandin on Interval Intraocular Pressure in Intravitreal Injection - a Randomised Controlled Prospective Study

Clinical trial2021-04-01Completed · ClinicalTrials.gov

A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004%

Clinical trial2019-03-28Completed · ClinicalTrials.gov

Clinical trial2017-04-01Completed · ClinicalTrials.gov

Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Clinical trial2016-07-28Results posted · ClinicalTrials.gov

A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation

Clinical trial2016-02-01Completed · ClinicalTrials.gov

The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation

Clinical trial2016-01-18Results posted · ClinicalTrials.gov

A Prospective, Multicenter, Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Clinical trial2015-12-01Completed · ClinicalTrials.gov

Marketing authorisation: Izba (EMA)

Regulatory2014-02-20EMA

Marketing authorisation: Travatan (EMA)

Regulatory2001-11-27EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Travoprost

Aliases & brands

OTX-TPTRAVOPROST COMPONENT OF DUOTRAVTravataniDosetravoprost ophthalmic(1R-(1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.))-7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOIC ACID, 1-METHYLETHYL ESTERISOPROPYL (Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3R)-3-HYDROXY-4-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATETravoprostum

RxNorm CUI

283809

ChEMBL ID

CHEMBL1200799

ATC codes

S01EE04

UNII

WJ68R08KX9

Primary mechanism

Prostanoid FP receptor agonist

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Prostaglandin F2-alpha receptor

PTGFR · P43088

AGONISTProstanoid FP receptor agonist

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2001-11-27

Latest approval

2014-02-20

Authorities

EMA

Total events

emaEuropean Medicines Agency· 2 events

2014-02-20Original application approval

Marketing authorisation: Izba (EMA)

Indication: Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in… Show full indication

Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.

Evidence ↗

2001-11-27Original application approval

Marketing authorisation: Travatan (EMA)

Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).

Evidence ↗